Evaluation of clinical outcomes, laboratory and imaging data of patients with solid tumor infected with COVID-19 infection.

Autor:	Sadeghi S; Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences Isfahan, Iran.; Acquired Immunodeficiency Research Center, Al-Zahra Hospital, Isfahan University of Medical Sciences Isfahan, Iran., Peikar M; Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences Isfahan, Iran., Sadeghi E; Research Consultation Center (RCC), Shiraz University of Medical Sciences Shiraz, Iran., Darakhshandeh A; Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences Isfahan, Iran., Ghafel S; Mycology Reference Laboratory, Research Core Facilities Laboratory, Isfahan University of Medical Sciences Isfahan, Iran., Aalinezhad M; Department of Radiology, Medical School, Isfahan University of Medical Sciences Isfahan, Iran., Sadeghi A; Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences Isfahan, Iran., Sharifi M; Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences Isfahan, Iran.; Cancer Prevention Research Center, Seyed Al-Shohada Hospital, Isfahan University of Medical Sciences Isfahan, Iran., Nasri E; Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences Isfahan, Iran.
Jazyk:	angličtina
Zdroj:	International journal of biochemistry and molecular biology [Int J Biochem Mol Biol] 2022 Dec 15; Vol. 13 (6), pp. 77-86. Date of Electronic Publication: 2022 Dec 15 (Print Publication: 2022).
Abstrakt:	Background: COVID-19 is associated with higher mortality rates in patients with cancer. In this study, we aimed to evaluate the clinical outcomes, and laboratory and imaging data of patients with solid tumor infected with COVID-19 infection. Methods: This is a cross-sectional retrospective study performed in 2020-2022 on 85 patients with a previous diagnosis of solid tumors infected with COVID-19. We included all patients with tumors of solid organs that were diagnosed with COVID-19 infection and required hospitalization those patients previously hospitalized for treatments and were infected with COVID-19 during hospitalization. Demographic data of patients were collected using a checklist. We collected data regarding clinical outcome (discharge, hospitalization or death), duration of hospitalization, requiring ICU admission, duration of hospitalization divided by received drugs and type of tumor and mean survival time. Furthermore, we collected laboratory data from all patients. The radiologic characteristics of patients were also extracted from their data. Results: Breast cancer was the most common solid tumor (34.9%), followed by lung cancer (19.3%). The mortality rate was 24.1% (20 patients). The highest mortality rate in this study was for metastatic intestinal cancer to the lung (100%, one patient), followed by metastatic prostatic cancer to lung (50%, three patients). The highest hospitalization duration was for patients with glioblastoma multiform (GBM) (30 days). The mean survival time among patients with mortality was 19.15±1.80 days. The mean CT severity score of all patients was 27.53±22.90. Patient's most common radiologic sign was air space consolidation (89.1%). The highest CT severity score was found in patients with stomach cancer (46.67±5.77). Conclusion: The mortality rate in this study was 24.1%. Based on the results of our study and previous research, special care should be provided to patients with solid tumors during the COVID-19 pandemic and in infected cases. Competing Interests: None. (IJBMB Copyright © 2022.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu